N(dimethyl-1,1 oxo-2 propyl) propionamide | 77489-51-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N(dimethyl-1,1 oxo-2 propyl) propionamide
• 英文别名: N-(2-methyl-3-oxobutan-2-yl)propanamide
• CAS: 77489-51-1
• 化学式: C₈H₁₅NO₂
• 分子量: 157.213
• InChiKey: CUBCZLIRVPPNGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,2-dimethyl-3-oxo-butyric acid; potassium salt 、 丙腈 以42%的产率得到N(dimethyl-1,1 oxo-2 propyl) propionamide
  参考文献：
  名称：

  Chkir, Moncef; Lelandais, Daniel; Bacquet, Cathy, Canadian Journal of Chemistry, 1981, vol. 59, p. 945 - 951

  摘要：

  DOI：

文献信息

• Novel high affinity quinoline-based kinase ligands
  申请人：Deng Yongqi

  公开号：US20080045568A1

  公开（公告）日：2008-02-21

  Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.

  基于喹啉的细胞周期蛋白依赖激酶2抑制剂，包括这些抑制剂的组合物，以及使用这些抑制剂和抑制剂组合物的方法。这些抑制剂和包括它们的组合物对治疗疾病或疾病症状有用。该发明还提供了制备CDK-2抑制剂化合物的方法，抑制CDK-2的方法，以及治疗疾病或疾病症状的方法。
• LINKED DIBENZIMIDAZOLE ANTIVIRALS
  申请人：Qiu Yao-Ling

  公开号：US20100266543A1

  公开（公告）日：2010-10-21

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• US7511063B2
  申请人：——

  公开号：US7511063B2

  公开（公告）日：2009-03-31
• US8314135B2
  申请人：——

  公开号：US8314135B2

  公开（公告）日：2012-11-20